MH & Associates Securities Management Corp ADV Makes New Investment in Bristol Myers Squibb Company $BMY

MH & Associates Securities Management Corp ADV purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,902 shares of the biopharmaceutical company’s stock, valued at approximately $1,181,000.

A number of other large investors also recently made changes to their positions in BMY. Man Group plc lifted its stake in shares of Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the period. Two Sigma Investments LP lifted its stake in shares of Bristol Myers Squibb by 530.6% during the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after purchasing an additional 4,588,601 shares during the period. Van ECK Associates Corp lifted its stake in shares of Bristol Myers Squibb by 67.8% during the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of Bristol Myers Squibb by 31.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock worth $669,012,000 after purchasing an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 56.0% during the 3rd quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after purchasing an additional 3,396,041 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 2.6%

Shares of NYSE BMY opened at $59.20 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a market cap of $120.86 billion, a P/E ratio of 17.16, a P/E/G ratio of 0.17 and a beta of 0.27. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The stock has a fifty day moving average price of $59.60 and a 200 day moving average price of $52.98.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the company posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.35.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.